|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
21
|
|
pubmed:dateCreated |
2004-9-29
|
|
pubmed:abstractText |
Structure-activity relationships (SAR) of a weakly active class of CCR2b inhibitors were utilized to initiate a lead evolution program employing the Drug Discovery Engine. Several alternative structural series have been discovered that display nanomolar activity in the CCR2b binding and CCR2b-mediated chemotaxis assays.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0960-894X
|
|
pubmed:author |
pubmed-author:BarnumDougD,
pubmed-author:EndoNoriakiN,
pubmed-author:GreeneJonathanJ,
pubmed-author:HadaTakahikoT,
pubmed-author:ImaiMinoruM,
pubmed-author:KataokaKen-ichiroK,
pubmed-author:KatoYoshinoriY,
pubmed-author:MoreeWilna JWJ,
pubmed-author:MoritaTakuyaT,
pubmed-author:MurogaYumikoY,
pubmed-author:MyersPeter LPL,
pubmed-author:Ramirez-WeinhouseMichele MMM,
pubmed-author:SaundersJohnJ,
pubmed-author:ShiotaTatsukiT,
pubmed-author:SudoMasakiM,
pubmed-author:TanakaHirokoH,
pubmed-author:TarbyChristine MCM,
pubmed-author:TsutsumiTakaharuT
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5413-6
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15454236-Cell Line,
pubmed-meshheading:15454236-Chemokine CCL2,
pubmed-meshheading:15454236-Chemotaxis,
pubmed-meshheading:15454236-Combinatorial Chemistry Techniques,
pubmed-meshheading:15454236-Diamines,
pubmed-meshheading:15454236-Drug Design,
pubmed-meshheading:15454236-Humans,
pubmed-meshheading:15454236-Piperidines,
pubmed-meshheading:15454236-Pyrrolidines,
pubmed-meshheading:15454236-Radioligand Assay,
pubmed-meshheading:15454236-Receptors, CCR2,
pubmed-meshheading:15454236-Receptors, Chemokine,
pubmed-meshheading:15454236-Structure-Activity Relationship
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Small molecule antagonists of the CCR2b receptor. Part 2: Discovery process and initial structure-activity relationships of diamine derivatives.
|
|
pubmed:affiliation |
Deltagen Research Laboratories, 4570 Executive Drive, Suite 400, San Diego, CA 92121, USA. wmoree@neurocrine.com
|
|
pubmed:publicationType |
Journal Article
|
